TY - JOUR
T1 - Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
AU - Levine, John E.
AU - Grupp, Stephan A.
AU - Pulsipher, Michael A.
AU - DIetz, Andrew C.
AU - Rives, Susana
AU - Myers, G. Douglas
AU - August, Keith J.
AU - Verneris, Michael R.
AU - Buechner, Jochen
AU - Laetsch, Theodore W.
AU - Bittencourt, Henrique
AU - Baruchel, Andre
AU - Boyer, Michael W.
AU - De Moerloose, Barbara
AU - Qayed, Muna
AU - Davies, Stella M.
AU - Phillips, Christine L.
AU - Driscoll, Timothy A.
AU - Bader, Peter
AU - Schlis, Krysta
AU - Wood, Patricia A.
AU - Mody, Rajen
AU - Yi, Lan
AU - Leung, Mimi
AU - Eldjerou, Lamis K.
AU - June, Carl H.
AU - Maude, Shannon L.
N1 - Funding Information:
Competing interests JEL has received research and/or clinical trial support from Incyte, Kamada, Mesoblast, and Biogen and has participated in consulting, study steering committees, or scientific/clinical advisory boards for Novartis, bluebird bio, Incyte, Ironwood, Mesoblast, Omeros, Oncoimmune, Talaris, and X4 Pharmaceuticals. SAG has received research and/or clinical trial support from Novartis, Servier, and Kite and has participated in consulting, study steering committees, or scientific/clinical advisory boards for Novartis, Cellectis, Adaptimmune, Eureka, TCR2, Juno, GlaxoSmithKline, Vertex, Cure Genetics, Humanigen, and Roche. MAP has participated in steering committees for the ENSIGN and ELIANA trials for Novartis, advisory boards, and educational activities for Novartis. ACD is a current employee of bluebird bio; bluebird bio has had no support or oversight of this research or manuscript. SR has received clinical trial support from Novartis, Servier, and Celgene and has participated in consulting, study steering committees, or scientific/clinical advisory boards for Novartis, Servier, Celgene, Cellectis, Kite/Bristol-Myers Squibb, JazzPharma, and Amgen. GDM has received payment and honoraria as a consultant to Novartis Pharma and for serving on the speaker’s bureau for Kymriah. KJA has participated in a speaker bureau and received travel accommodations and expenses from Novartis. MRV has participated in advisory boards for Novartis, Fate Therapeutics, and B-Mogen and has stock options from Fate Therapeutics and B-Mogen. JB has participated in study steering committees, advisory boards, and educational activities for Novartis, and advisory boards for Kite and Janssen. TWL has consulted for Novartis, Cellectis, Loxo Oncology, Eli Lilly, and Bayer; has received research funding from Novartis, Pfizer, and Bayer; and is currently affiliated with the Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA and the Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. HB has participated in consulting for Novartis and Jazz Pharmaceuticals and his department has received financial reimbursement for participation in tisagenlecleucel trials for Novartis. AB has received research and/or clinical trial support from Novartis, Servier, and Kite and participated in consulting, study steering committees, or scientific/clinical advisory boards for Novartis, Servier, Celgene, Jazz Pharma, AstraZeneca, Janssen, and Amgen. MWB has participated in advisory boards for Novartis and Thunder Biotech. BDM has received a travel grant from Jazz Pharma; her department has received financial reimbursement and compensation for participation in CTL019 trials for Novartis, and consulting for Novartis. MQ has received support for service on clinical advisory boards for Novartis and Bristol-Myers Squibb. SMD has received research support from Alexion Pharmaceuticals and served in a consulting role for Novartis. CLP has received support for service on clinical advisory board for Novartis.TAD has no conflicts to declare. PB has received institutional research grants from medac, Riemser, and Neovii and institutional compensation for advisory activity and speakers bureau from Miltenyi, Amgen, Novartis, Servier, medac, and Riemser. KS has no conflicts to declare. PAW was an employee of Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. RM has no conflicts to declare. LY is an employee of Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. ML is an employee of Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. LKE is an employee of Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. CHJ has received research support from Novartis and Tmunity Therapeutics. SLM has received clinical trial support from Novartis and has served in a consulting role, on advisory boards, or on study steering committees for Novartis, Kite, and Wugen.
Funding Information:
Funding These studies and writing assistance were funded by Novartis
Publisher Copyright:
©
PY - 2021/8/5
Y1 - 2021/8/5
N2 - Background Tisagenlecleucel, an anti-CD19 chimeric antigen receptor T cell therapy, has demonstrated efficacy in children and young adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) in two multicenter phase 2 trials (ClinicalTrials.gov, NCT02435849 (ELIANA) and NCT02228096 (ENSIGN)), leading to commercialization of tisagenlecleucel for the treatment of patients up to age 25 years with B-ALL that is refractory or in second or greater relapse. Methods A pooled analysis of 137 patients from these trials (ELIANA: n=79; ENSIGN: n=58) was performed to provide a comprehensive safety profile for tisagenlecleucel. Results Grade 3/4 tisagenlecleucel-related adverse events (AEs) were reported in 77% of patients. Specific AEs of interest that occurred ≤8 weeks postinfusion included cytokine-release syndrome (CRS; 79% (grade 4: 22%)), infections (42%; grade 3/4: 19%), prolonged (not resolved by day 28) cytopenias (40%; grade 3/4: 34%), neurologic events (36%; grade 3: 10%; no grade 4 events), and tumor lysis syndrome (4%; all grade 3). Treatment for CRS included tocilizumab (40%) and corticosteroids (23%). The frequency of neurologic events increased with CRS severity (p<0.001). Median time to resolution of grade 3/4 cytopenias to grade ≤2 was 2.0 (95% CI 1.87 to 2.23) months for neutropenia, 2.4 (95% CI 1.97 to 3.68) months for lymphopenia, 2.0 (95% CI 1.87 to 2.27) months for leukopenia, 1.9 (95% CI 1.74 to 2.10) months for thrombocytopenia, and 1.0 (95% CI 0.95 to 1.87) month for anemia. All patients who achieved complete remission (CR)/CR with incomplete hematologic recovery experienced B cell aplasia; however, as nearly all responders also received immunoglobulin replacement, few grade 3/4 infections occurred >1 year postinfusion. Conclusions This pooled analysis provides a detailed safety profile for tisagenlecleucel during the course of clinical trials, and AE management guidance, with a longer follow-up duration compared with previous reports.
AB - Background Tisagenlecleucel, an anti-CD19 chimeric antigen receptor T cell therapy, has demonstrated efficacy in children and young adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) in two multicenter phase 2 trials (ClinicalTrials.gov, NCT02435849 (ELIANA) and NCT02228096 (ENSIGN)), leading to commercialization of tisagenlecleucel for the treatment of patients up to age 25 years with B-ALL that is refractory or in second or greater relapse. Methods A pooled analysis of 137 patients from these trials (ELIANA: n=79; ENSIGN: n=58) was performed to provide a comprehensive safety profile for tisagenlecleucel. Results Grade 3/4 tisagenlecleucel-related adverse events (AEs) were reported in 77% of patients. Specific AEs of interest that occurred ≤8 weeks postinfusion included cytokine-release syndrome (CRS; 79% (grade 4: 22%)), infections (42%; grade 3/4: 19%), prolonged (not resolved by day 28) cytopenias (40%; grade 3/4: 34%), neurologic events (36%; grade 3: 10%; no grade 4 events), and tumor lysis syndrome (4%; all grade 3). Treatment for CRS included tocilizumab (40%) and corticosteroids (23%). The frequency of neurologic events increased with CRS severity (p<0.001). Median time to resolution of grade 3/4 cytopenias to grade ≤2 was 2.0 (95% CI 1.87 to 2.23) months for neutropenia, 2.4 (95% CI 1.97 to 3.68) months for lymphopenia, 2.0 (95% CI 1.87 to 2.27) months for leukopenia, 1.9 (95% CI 1.74 to 2.10) months for thrombocytopenia, and 1.0 (95% CI 0.95 to 1.87) month for anemia. All patients who achieved complete remission (CR)/CR with incomplete hematologic recovery experienced B cell aplasia; however, as nearly all responders also received immunoglobulin replacement, few grade 3/4 infections occurred >1 year postinfusion. Conclusions This pooled analysis provides a detailed safety profile for tisagenlecleucel during the course of clinical trials, and AE management guidance, with a longer follow-up duration compared with previous reports.
KW - chimeric antigen
KW - hematologic neoplasms
KW - pediatrics
KW - receptors
UR - http://www.scopus.com/inward/record.url?scp=85112267200&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112267200&partnerID=8YFLogxK
U2 - 10.1136/jitc-2020-002287
DO - 10.1136/jitc-2020-002287
M3 - Article
C2 - 34353848
AN - SCOPUS:85112267200
VL - 9
JO - Journal for ImmunoTherapy of Cancer
JF - Journal for ImmunoTherapy of Cancer
SN - 2051-1426
IS - 8
M1 - 002287
ER -